28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Third, in many cases, Susac syndrome is diagnosed and treated late, with significant irreversible sequelae including dementia, blindness and hearing loss. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among individuals with mild cognitive impairment, no vision impairment (VI) and corrected VI were associated with a lower risk of dementia than uncorrected VI, particularly among those aged < 75 years. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This case report is of a two-time stroke survivor with significant health comorbidities. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source
Sensory impairments (e.g., decreased function in hearing, vision, olfaction, and other senses) may be risk factors for or early markers of Alzheimer's disease (AD) and related dementias (ADRD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cardiovascular risk factors contribute to the majority of dementia cases, with about 20% directly attributable to vascular cognitive impairment and dementia (VCID). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes, elevated fasting glucose, central obesity, and heart age greater than chronological age were associated with rate of decline in processing speed during midlife. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Preserved executive functioning (EF) is crucial for daily functioning in the elderly and it appears to predict dementia development. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Higher educational attainment is observationally associated with lower risk of Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Studies of neurodegenerative disease risk in gout are contradictory. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive reserve (CR) explains interindividual differences in the ability to maintain cognitive function in the presence of neuropathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late-life depression (LLD) is associated with cognitive decline and increased risk of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Social activity was associated with global cognition, perceptual speed, perceptual orientation, and episodic memory over time. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
An interquartile range increase in 20-year PM2.5 was associated with a 20% higher risk of dementia (95% confidence interval [CI]: 5%, 37%) and an increased risk of mixed VaD/AD but not AD alone. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The neuropathological hallmarks of Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS) are present in urban children exposed to fine particulate matter (PM2.5), combustion and friction ultrafine PM (UFPM), and industrial nanoparticles (NPs). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The scientific literature is scarce when referring to the influence of atmospheric pollutants on neurodegenerative diseases for present and future climate change scenarios. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We observed significant increases in all-cause hospital admissions (2.53% in PD and 2.49% in AD/dementia) attributable to high PM2.5 exposure. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
After a mean follow-up of 3.9 years, 131 persons developed Alzheimer disease. 5 key findings →
Participants: 131 Evidence: low
Full summary, score breakdown and related studies → Original source
Groups of spouse (N = 285) and adult child (N = 244) caregivers of elderly parents suffering from Alzheimer's disease were interviewed regarding their caregiving behaviors, evaluations of caregiving, and general psychological well-being. 1 key finding →
Participants: 285 Evidence: low
Full summary, score breakdown and related studies → Original source
More than 3500 Cochrane Reviews are now available in full, including information on the methods, eligible studies, analyses, results, and conclusions. 2 key findings →
Participants: 8,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Children with Down syndrome (DS) experience congenital and functional medical issues that predispose them to obstructive sleep apnea (OSA). 4 key findings →
Participants: 177 Evidence: low
Full summary, score breakdown and related studies → Original source
Fatty acid differences, including docosahexaenoic acid (DHA; 22:6n-3) have been shown in the brains of Alzheimer's patients (AD) as compared with normal age-matched individuals. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There is overwhelming evidence to suggest that the neuropathology of Alzheimer disease (AD) extends beyond amyloid plaques and neurofibrillary tangles. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A growing body of epidemiological evidence suggested that metabolic syndrome (MetS) and Mets components (impaired glucose tolerance, abdominal or central obesity, hypertension, hypertriglyceridemia, and reduced high-density lipoprotein cholesterol) may be important in the development of age-related cognitive decline (ARCD), mild cognitive impairment (MCI), vascular dementia, and Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Chronic inflammation is now considered to be central to the pathogenesis not only of such medical disorders as cardiovascular disease, multiple sclerosis, diabetes and cancer but also of major depression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is associated with major impairments in insulin and insulin-like growth factor (IGF) gene expression and signaling in the brain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →